Myriad Genetics Faces Declining Stock Performance Myriad Genetics' stock opened at $9.98, reflecting a 0.3% drop as of March 25, 2025. The company has faced challenges, including lowered price targets and a negative net margin of 14.09%. Analysts continue to provide mixed ratings, with the stock holding a consensus rating of "Hold."2